Corcept (CORT) Officer Buys Shares Under 2024 Plan; 256 Shares Withheld

Rhea-AI Filing Summary

Corcept Therapeutics (CORT) insider activity: Gary Charles Robb, Chief Business Officer, purchased common stock under the company's 2024 Incentive Award Plan Purchase Plan on September 2, 2025. He acquired 251 shares at a price based on the closing price of $71.38 on that date and separately acquired 251 shares under the Purchase Plan with a reported price of $0 for the restricted-plan component. On September 3, 2025 a transaction coded F shows 256 shares disposed at $71.38 for tax withholding related to vesting. Following these transactions he beneficially owned 13,610 shares directly and 11,571 shares indirectly held in a custodial account for a child. Several restricted stock awards (290, 292, 997 shares) remain unvested and vest one year after grant dates if conditions are met.

Positive

• Purchase under approved plan: Reporting Person acquired shares pursuant to the Corcept 2024 Incentive Award Plan Purchase Plan on 09/02/2025.
• Transparent vesting terms: Filing discloses specific unvested restricted stock award amounts (290, 292, 997 shares) and one-year vesting conditions.
• Custodial holdings disclosed: The report clearly identifies 11,571 shares held in a custodial account for a child with the Reporting Person as custodian.

Negative

• Tax withholding reduced net holdings: 256 shares were withheld/disposed on 09/03/2025 to satisfy tax withholding relating to vesting.

Insights

Securities/Insider Transactions Analyst

TL;DR: Officer executed routine purchase under company purchase plan and shares were withheld for tax following restricted stock vesting.

The filing documents an insider purchase under the company's 2024 Incentive Award Plan on 09/02/2025 and a subsequent withholding disposition on 09/03/2025 to satisfy tax obligations arising from vesting. The reported purchase used the closing price of $71.38 to set the purchase price and the filing discloses the composition of unvested restricted awards (290, 292, 997 shares) that vest on one-year anniversaries subject to ownership and service conditions. The report also clarifies custodial holdings of 11,571 shares for a minor for which the reporting person is custodian.

Corporate Governance Expert

TL;DR: Disclosure is standard and consistent with Section 16 reporting of insider purchases, vesting schedules, and tax-withholding.

The Form 4 provides clear disclosure of beneficial ownership changes by a named officer and includes required explanatory notes on purchase plan mechanics, price determination, restricted stock vesting terms, and tax-withholding via share surrender. Custodial indirect ownership is explicitly stated under the Uniform Transfers to Minors Act. No material corporate governance events or departures are reported.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Robb Gary Charles

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		A		251(1)	A	$71.38(2)	13,615(3)	D
Common Stock	09/02/2025		A		251(4)	A	$0	13,866(3)	D
Common Stock	09/03/2025		F(5)		256	D	$71.38(6)	13,610(3)	D
Common Stock								11,571	I	Custodial Account for Child(7)
Common Stock								11,571	I	Custodial Account for Child(8)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 2, 2025.

2. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

3. Includes 290 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025 and 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

4. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

5. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.

6. The closing price on September 2, 2025 was used to calculate the withholding obligation.

7. These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.

8. These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Gary Charles Robb.	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Gary Charles Robb report on Form 4 for CORT?

He reported purchases on 09/02/2025 under the 2024 Incentive Award Plan and a share withholding disposition on 09/03/2025 to satisfy tax obligations.

How many shares did the reporting person beneficially own after these transactions?

13,610 shares directly and 11,571 shares indirectly (held in a custodial account for a child) following the reported transactions.

What price was used for the September 2, 2025 purchase?

The Purchase Plan used the closing price of $71.38 on September 2, 2025 to establish the purchase price; one Purchase Plan entry shows $0 for the restricted-plan component as reported.

Why were shares disposed on September 3, 2025?

256 shares were withheld by the issuer to satisfy tax withholding obligations in connection with the issuance upon vesting of restricted stock units.

What restricted stock awards are outstanding for the reporting person?

Unvested awards include 290, 292, and 997 shares granted on 12/02/2024, 03/03/2025, and 06/02/2025 respectively; each vests 100% on the one-year anniversary of the grant date if conditions are met.